Pilot Study to Evaluate the Prevention and Safety of Doxorubicin-induced Cardiomyopathy Using Extracorporeal Shock Waves

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

72 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-10-01

Study Completion Date

2023-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Until now, patients receiving doxorubicin chemotherapy should use only the cumulative dose related to known cardiotoxicity, or if cardiotoxicity occurs below the known cumulative dose, use of doxorubicin as chemotherapy should be stopped. In this study, in patients with normal heart function receiving doxorubicin chemotherapy, extracorporeal shock wave therapy was performed 3 times a week during chemotherapy, and 1 cycle of extracorporeal shock wave therapy was performed (every 6 weeks) every 2 cycles of chemotherapy. Echocardiography should be performed at baseline and every 4 cycles of chemotherapy, and follow-up 3 months after chemotherapy is completed to compare the incidence of cardiomyopathy caused by chemotherapy between the two groups.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Docetaxel + Doxorubicin as Neoadjuvant Chemotherapy in Patients With Breast Cancer

NCT00461344

Ductal Carcinoma

TERMINATED PHASE2

MIBG Scintigraphy and Strain Echocardiography in the Detection of Subclinical Cardiovascular Effects One Year After (Neo)Adjuvant Breast Cancer Treatment With Docetaxel, Doxorubicin and Cyclophosphamide (TAC): a Pilot Study

NCT01246856

Breast Cancer

UNKNOWN

Neoadjuvant Chemotherapy With Docetaxel and Gemcitabine in Locally Advanced Breast Cancer

NCT01352494

Breast Cancer Stage II Breast Cancer Stage III

UNKNOWN PHASE2

Strain Echocardiography to Predict Cardiotoxicity in Patients Receiving Chemotherapy Containing Doxorubicin

NCT02423356

Breast Neoplasms Lymphoma Sarcoma

COMPLETED

Digoxin Induced Dissolution of CTC Clusters

NCT03928210

Breast Cancer Circulating Tumor Cells (CTCs)

COMPLETED EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

1. Extracorporeal shock wave therapy cycle

* For breast cancer patients using doxorubicin as the main anticancer agent, 1 cycle of extracorporeal shock wave therapy was performed every 2 cycles of chemotherapy.
* The extracorporeal shock wave therapy is targeted to the existing refractory angina pectoris patients and is based on the energy used in patients with ischemic heart disease without serious side effects. The treatment is performed 3 times a week in 1 cycle, 200 shots per spot. , a shock wave of 0.09mJ/mm2 energy was applied to 40-60 spots (8,19,20)
* Conventional chemotherapy is performed every 3 weeks, and the dose of doxorubicin used per session is 40-60 mg/m2, and considering the cumulative dose, chemotherapy is performed on average 6-8 times. Therefore, extracorporeal shock wave therapy is performed every 6 weeks, and a total of 3 to 4 times.
* It is expected that factors affecting efficacy will be controlled by targeting patients with the same carcinoma, the same chemotherapy, and no underlying heart disease. Since the cumulative doxorubicin dose can be received from a minimum of 60mg/m2 to a maximum of 400mg/m2, the cumulative dose of doxorubicin in the control and experimental groups should be divided into sections to further analyze the cardiomyopathy incidence rate and echocardiographic indicators.
* Extracorporeal shock wave therapy position and posture The extracorporeal shock wave probe is placed at the position where the apical view of the echocardiogram is taken, and the patient's posture is supine or lateral position. When extracorporeal shock wave therapy is performed in the following locations, the entire cardiac muscle can be included.
2. It was assumed that the incidence of cardiomyopathy in patients receiving extracorporeal shock wave therapy was low. Cardiomyopathy is defined as ① a decrease in the absolute value of left ventricular ejection fraction by 10% or more or ② a decrease in the absolute value of LV global longitudinal strain (GLS) by 8% or more. In this study, cardiomyopathy caused by the definition of LV global longitudinal strain (GLS) was set as the primary efficacy evaluation.

Therefore, when the target number of subjects is set according to the definition that the LV global longitudinal strain (GLS) set as the primary efficacy evaluation variable is reduced to less than 17.5%, the absolute LVGLS value is the dependent variable, the significance level is 0.05, and the power is based on 85%. Therefore, when the ratio between groups is 1:1, the mean of the treated group is expected to be 19.6%, the mean of the untreated group is expected to be 18.0%, and when the standard deviations are applied as 2.4% and 2.4%, respectively, when using the G\*Power 3.1 program, 33 people are required for each calculated group. Considering the dropout rate of 10%, 36 people each, a total of 72 subjects, is calculated as the required number of subjects.
3. Observational items/clinical examination items and observational examination method Basic information: Acquired at the time of clinical research registration

* Age, gender, height, weight, BMI, systolic diastolic blood pressure, pulse clinical information
* Clinical information 1: Acquired at the time of clinical research registration Accompanying diseases (hypertension, diabetes, dyslipidemia, chronic kidney disease, etc.), past acute reaction
* Clinical information 2: Acquired at the time of clinical study registration and every echocardiogram follow-up Breast cancer stage, doxorubicin dose used for chemotherapy, chemotherapy cycle medications taken within the past 4 weeks (including current medications);
* Diagnostic test results (Creatinie Kinase (CK), Creatine Kinase-MB (CK-MB), Troponin T (TnT), N-terminal pro-Brain natriuretic peptide (NT-proBNP), compete blood count (CBC), Chemistry) ,
* New York Heart Association (NYHA) classiciation - Class 1,2,3,4; It is obtained by dividing into Class 1, 2, 3, and 4 through a questionnaire about the patient's subjective symptoms, and is obtained through a questionnaire at the time of clinical study registration and every echocardiogram follow-up.
* Electrocardiogram (EKG). Chest X-ray (CXR) Echocardiographic parameters: Acquired at the time of clinical study registration and at each echocardiographic follow-up.

Left ventricular ejection fraction (LVEF), Left ventricular end-diastolic dimension (LVEDD), Left ventricular end-systolic dimension (LVESD), Inter-ventricular septal diastolic phase (IVSd), Posterior wall thickness (PWd), Mitral inflow pattern, Mitral valve tissue doppler, Rightly ventricular systolic pressure (RVSP), Left ventricular (LV) global longitudinal strain

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control group

Group not using drugs used for the prevention of cardiomyopathy caused by doxorubicin, including extracorporeal shock wave

Group Type NO_INTERVENTION

No interventions assigned to this group

ESWT treatment group

Group receiving extracorporeal shock wave therapy

Group Type EXPERIMENTAL

Extracorporeal shock waves

Intervention Type DEVICE

3 times of extracorporeal shock wave therapy is performed, and 1 cycle of extracorporeal shock wave therapy is performed (every 6 weeks) every 2 cycles of chemotherapy. Echocardiography is performed at baseline and every 4 cycles of chemotherapy.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Extracorporeal shock waves

3 times of extracorporeal shock wave therapy is performed, and 1 cycle of extracorporeal shock wave therapy is performed (every 6 weeks) every 2 cycles of chemotherapy. Echocardiography is performed at baseline and every 4 cycles of chemotherapy.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Breast cancer patients receiving doxorubicin chemotherapy (for patients with operable breast cancer who receive doxorubicin with neoadjuvant or adjuvant chemotherapy)
2. Patients who are expected to receive at least 3 cycles of doxorubicin chemotherapy after registration and who can receive at least 2 extracorporeal shock wave therapy
3. Those with a left ventricular ejection fraction of 50% or more at screening

Exclusion Criteria

1. Subjects under the age of 19
2. Those who have implanted an intracardiac device (implantable defibrillator, pacemaker)
3. Hemodynamically unstable ventricular tachycardia confirmed
4. If you have QT prolongation syndrome or are receiving medication that increases QT interval

* Antiarrhythmics class IA; quinidine, procainamide
* Antiarrhythmics class III; amiodarone, sotalol
5. Patients with atrial fibrillation or those who have undergone defibrillation for atrial fibrillation within the last 3 months
6. In case of structural heart disease (congenital heart disease, valvular disease, etc.) and related surgery
7. Persons who have had coronary artery disease or a subsequent PCI or coronary artery bypass surgery
8. Those with symptoms of unstable angina requiring hospitalization
9. Persons suspected or diagnosed with cardiomyopathy due to causes other than chemotherapy
10. When life expectancy is less than 6 months
11. Pregnant women or those planning to become pregnant
12. Moderate or severe hepatic impairment (ex. Child-Pugh class B,C)
13. Creatinine clearance \< 30mL/min
14. Patients judged to be inappropriate by other researchers

Minimum Eligible Age

19 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes